Top Markets
#1 Official Trump Official Trump +51.60%
#2 Movement Movement +32.33%
#3 Mubarak Mubarak +26.27%
#4 Pearl Pearl +24.49%
#5 Zama Zama +24.44%
#6 Melania Meme Melania Meme +22.38%
#7 EXOD EXOD +18.93%
#8 Wrapped POL Wrapped POL +18.74%
#9 POL (ex-MATIC) POL (ex-MATIC) +18.66%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +16.92%
Coin of the day
Official Trump Official Trump
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Citius Oncology, Inc. Citius Oncology, Inc.

Citius Oncology, Inc.

CTOR
Rangering i aksjer #23802
Citius Oncology, Inc. concentrates on advancing innovative, targeted... Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Aksjekurs
$0.7426
Sist synkronisert: 2026-08-21
Markedsverdi
$69.05M
Endring (1 dag)
-2.17%
Endring (1 år)
-57.57%
Land
US
Handel Citius Oncology, Inc. (CTOR)

Kategori

Healthcare
Utbytteavkastning for Citius Oncology, Inc. (CTOR)
Citius Oncology, Inc. (aksjesymbol: CTOR) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Citius Oncology, Inc. (CTOR) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
Ikke nok data for de angitte datoene.
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
Selskap Utbytteavkastning Land
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
0.57%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
2.01%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
2.74%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
2.69%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
2.47%
US